Acro Biomedical (ACBM) Price to Sales (2018 - 2022)

Acro Biomedical has reported Price to Sales for 5 years, with the latest figure at 750.52 in Q4 2022.

• On a quarterly basis, Price to Sales rose 60.75% year-over-year to 750.52 in Q4 2022; TTM through Sep 2023 was 250.18, a 6.38% decrease from a year earlier, with the FY2022 full-year figure at 326.38, up 75.99% from the prior year.
• Price to Sales was 750.52 for Q4 2022 at Acro Biomedical, down from 804.58 in the prior quarter.
• The five-year high for Price to Sales was 1440.0 in Q1 2021, with the low at 61.52 in Q3 2018.
• Average Price to Sales over 5 years is 501.78, with a median of 360.51 recorded in 2021.
• The sharpest annual moves came in 2021 and 2022: Price to Sales surged 926.86% in 2021, then plunged 44.13% in 2022.
• Over 5 years, Price to Sales stood at 135.8 in 2018, then surged by 561.45% to 898.26 in 2019, then plunged by 84.39% to 140.23 in 2020, then jumped by 232.93% to 466.88 in 2021, then jumped by 60.75% to 750.52 in 2022.
• The last three Price to Sales figures came in at 750.52 (Q4 2022), 804.58 (Q1 2022), and 466.88 (Q4 2021), per Business Quant data.